Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.RTTR · Entity 7776 | Director | January 21, 2020 | April 23, 2020 |
| OmniAb, Inc.OABI · Entity 5294 | Director · President and CEO | April 07, 2026 | April 08, 2026 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date January 21, 2020 · Filed April 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 138,635 |
Ending reported balance
After 2020-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-21 · Conversion · Acquired 76,923 · Balance 100,174 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. Row 2 · 2020-04-10 · Grant · Acquired 38,461 · Balance 138,635 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
| Series B convertible preferred stockSEC Table II · derivative / convertible security · Conversion / exercise price $1.30 | Direct | 0 |
Reported balance
After 2020-01-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-21 · Conversion · Disposed 100 · Balance 0 F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date. |
| Warrant Shares (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2023-11-05 | Direct | 0 |
Reported balance
After 2020-04-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-04-10 · Disposition to issuer · Disposed 38,461 · Balance 0 F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person converted 100 shares of Series B convertible preferred stock on January 21, 2020, at a conversion price of $1.30 per share, resulting in his acquisition of 76,923 shares of common stock. The Series B convertible preferred stock had a stated value of $1,000 per share, was convertible at any time, and had no expiration date.
F2: The Reporting Person disposed of warrants to purchase 38,461 shares of the Issuer's common stock in exchange for 38,461 shares of the Issuer's common stock pursuant to an exchange agreement with the Issuer in reliance on Section 3(a)(9) of the Securities Act of 1933, as amended.
OmniAb, Inc.
Report date April 07, 2026 · Filed April 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,420,492 |
Ending reported balance
After 2026-04-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-07 · Exercise / conversion · Acquired 36,459 · Balance 4,439,736 F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-04-07 · Sale · Disposed 19,244 · Balance 4,420,492 F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 309,376 |
Reported balance
After 2026-04-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-07 · Exercise / conversion · Disposed 36,459 · Balance 309,376 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F3: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and do not represent discretionary trades by the reporting person.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.46 to $1.53. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Viking Therapeutics, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 135,186 |
Ending reported balance
After 2026-01-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-01-02 · Exercise / conversion · Acquired 16,000 · Balance 148,036 Row 2 · 2026-01-02 · Sale · Disposed 16,000 · Balance 132,036 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Row 3 · 2026-01-02 · Grant · Acquired 3,150 · Balance 135,186 F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.33 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2026-01-02 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-02 · Exercise / conversion · Disposed 16,000 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.42 · Expires 2036-01-02 | Direct | 20,400 |
Reported balance
After 2026-01-02 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-02 · Grant · Acquired 20,400 · Balance 20,400 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.94 to $35.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LIGAND PHARMACEUTICALS INC
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 162,187 |
Reported balance
After 2022-11-01 transaction · row 1
1 source rowRow 1 · 2022-11-01 · Disposition to issuer · Disposed 20,304 · Balance 162,187 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $90.68 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 34,214 · Balance 0 F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022.
F2: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
OmniAb Operations, Inc.
Report date November 01, 2022 · Filed November 04, 2022
Section 16 reporting ended · disclosed 2022-11-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 212,362 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Grant · Acquired 26,193 · Balance 212,362 F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire. F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-11-01 · Disposition to issuer · Disposed 212,362 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 60,878 |
Reported balance
After 2022-11-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-11-01 · Grant · Acquired 60,878 · Balance 60,878 F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $50.96 · Expires 2032-05-05 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-11-01 · Disposition to issuer · Disposed 60,878 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $41.82 · Expires 2024-02-12 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-11-01 · Disposition to issuer · Disposed 55,222 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $31.62 · Expires 2025-02-10 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-11-01 · Disposition to issuer · Disposed 35,258 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $48.21 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-11-01 · Disposition to issuer · Disposed 22,660 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $56.41 · Expires 2027-02-24 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-11-01 · Disposition to issuer · Disposed 21,271 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $89.36 · Expires 2028-03-02 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-11-01 · Disposition to issuer · Disposed 17,711 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F6: The stock option is fully vested and exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $66.30 · Expires 2029-02-11 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-11-01 · Disposition to issuer · Disposed 29,861 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $53.77 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-11-01 · Disposition to issuer · Disposed 29,012 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $99.75 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-11-01 · Disposition to issuer · Disposed 11,475 · Balance 0 F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement. F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022. F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 16,258 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock and does not expire.
F2: Includes 166,493 shares of the Issuer's Common Stock received by the Reporting Person in connection with a pro-rata distribution in-kind from Ligand Pharmaceuticals Incorporated, which was exempt from reporting pursuant to Rule 16a-9.
F3: Includes securities that were amended pursuant to an anti-dilution provision in connection with the separation of the Issuer from Ligand Pharmacueticals Incorporated on November 1, 2022.
F4: Pursuant to the business combination of Avista Public Acquisition Corp. II (after consummation of the transaction contemplated here, "New OmniAb") and the Issuer, as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of the Issuer will automatically convert into the right to receive securities of New OmniAb with the same terms and conditions in accordance with exchange ratios described in the Merger Agreement.
F5: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter.
F6: The stock option is fully vested and exercisable.
F7: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter.
F8: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter.
F9: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 07, 2024 Filed Apr 9, 2024 22:38 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 36,458 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002001011-24-000045 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,188,874 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on April 7, 2024. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionStock Option (right to buy) · Derivative | 150,391 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0002001011-24-000037 · edgardoc.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 505,859 Underlying: Common Stock · 150,391 shares Expires 2033-04-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionStock Option (right to buy) · Derivative | 93,222 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0002001011-24-000037 · edgardoc.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,089 Underlying: Common Stock · 93,222 shares Expires 2032-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 150,391 | $3.75 | $563,966.25 |
DisclosureSEC source: 0002001011-24-000037 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,152,416 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 27, 2024 Filed Mar 29, 2024 20:52 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 93,222 | $3.68 | $343,056.96 |
DisclosureSEC source: 0002001011-24-000037 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,002,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2024 Filed Mar 25, 2024 11:07 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 225,000 | $5.19 | $1,167,750.00 |
DisclosureSEC source: 0002001011-24-000033 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,908,803 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.110 to $5.295 The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option (right to buy) · Derivative | 656,250 | $0.00 Strike: $5.64 | $0.00 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,250 Underlying: Common Stock · 656,250 shares Expires 2034-02-16 F6 · derivative.exercise_date: The Stock Option grant vests and is exercisable as to 12.5% of the underlying shares 6 months after the grant date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantRestricted Stock Units · Derivative | 109,375 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298,408 Underlying: Common Stock · 109,375 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F5 · derivative.exercise_date: The RSU grant vests in three substantially equal annual installments beginning on February 16, 2025. F5 · derivative.expiration_date: The RSU grant vests in three substantially equal annual installments beginning on February 16, 2025. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 26,558 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,033 Underlying: Common Stock · 26,558 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. F4 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 10,770 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215,591 Underlying: Common Stock · 10,770 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents the vesting of an RSU grant which occurs in two substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. F1 · derivative.expiration_date: Represents the vesting of an RSU grant which occurs in two substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 13,460 | $5.54 | $74,568.40 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · nonDerivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,683,803 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported RSUs. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 26,558 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,697,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents the vesting of an RSU grant which occurs in three substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 5,459 | $5.54 | $30,242.86 |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,670,705 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported RSUs. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 23:22 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 10,770 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002001011-24-000021 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,676,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the vesting of an RSU grant which occurs in two substantially equal annual installments beginning on February 15, 2023, as per the terms of the November 2022 Business Combination. F2 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:42 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 33,173 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000005 · edgardoc.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 226,361 Underlying: Common Stock · 33,173 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. Units vested in full December 31, 2023, and have been released January 2, 2024. F1 · derivative.exercise_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. Units vested in full December 31, 2023, and have been released January 2, 2024. F1 · derivative.expiration_date: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. Units vested in full December 31, 2023, and have been released January 2, 2024. Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:42 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 13,221 | $6.25 | $82,631.25 |
DisclosureSEC source: 0002001011-24-000005 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,665,394 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units ("RSUs"). Read SEC document |
| January 02, 2024 Filed Jan 3, 2024 22:42 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 33,173 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002001011-24-000005 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,678,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of the Issuer's Common Stock. Units vested in full December 31, 2023, and have been released January 2, 2024. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 02:22 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $18.28 | $0.00 |
DisclosureSEC source: 0001209191-24-000921 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2034-01-02 Read SEC document |
| December 12, 2023 Filed Dec 13, 2023 20:25 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 200,000 | $5.05 | $1,010,000.00 |
DisclosureSEC source: 0002001011-23-000015 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,645,442 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.885 to $5.130. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2023 Filed Dec 12, 2023 00:24 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionRestricted Stock Units · Derivative | 26,556 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-23-000009 · edgardoc.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,534 Underlying: Common Stock · 26,556 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.exercise_date: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F1 · derivative.expiration_date: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| December 07, 2023 Filed Dec 12, 2023 00:24 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 9,184 | $4.85 | $44,542.40 |
DisclosureSEC source: 0002001011-23-000009 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,445,442 F3 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units ("RSUs"). Read SEC document |
| December 07, 2023 Filed Dec 12, 2023 00:24 UTC | OmniAb, Inc. OABI · Entity 5294 | Exercise / conversionCommon Stock | 26,556 | Not disclosed | Not disclosed |
DisclosureSEC source: 0002001011-23-000009 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,454,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three substantially equal annual installments beginning on December 07, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. F2 · balance_after: The total includes 151 shares acquired on November 30, 2023, through the Issuer's Employee Stock Purchase Plan (ESPP). Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 13:00 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 95,000 | $4.27 | $405,517.00 |
DisclosureSEC source: 0000950170-23-062463 · ownership.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,427,919 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.175 to $4.6. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2023 Filed Aug 15, 2023 20:56 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 45,000 | $5.48 | $246,600.00 |
DisclosureSEC source: 0001846253-23-000099 · primary_doc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,332,919 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.370 to $5.590. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · balance_after: The Reporting Person previously reported certain awards of Restricted Stock Units (RSUs) in Table I of Form 4, but has elected to report the RSUs in Table II going forward. As a result, the total reported in Column 5 of Table I has been updated to subtract 286,090 RSUs outstanding on August 14, 2023. Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 20:47 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 115,000 | $4.52 | $519,800.00 |
DisclosureSEC source: 0001846253-23-000079 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,574,009 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.495 to $4.560. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| May 12, 2023 Filed May 15, 2023 20:02 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 440,000 | $3.40 | $1,496,000.00 |
DisclosureSEC source: 0001846253-23-000072 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,438,414 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.295 to $3.510. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| April 07, 2023 Filed Apr 11, 2023 23:11 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 656,250 | $0.00 Strike: $3.75 | $0.00 |
DisclosureSEC source: 0001846253-23-000042 · edgardoc.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,250 Underlying: Common Stock · 656,250 shares Expires 2033-04-07 F2 · derivative.exercise_date: The Stock Option vests and is exercisable as to 12.5% of the underlying shares 6 months after the Grant Date, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| April 07, 2023 Filed Apr 11, 2023 23:11 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 109,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001846253-23-000042 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,998,414 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments beginning on each anniversary following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:28 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 4,177 | $3.80 | $15,872.60 |
DisclosureSEC source: 0001846253-23-000013 · edgardoc.xml · nonDerivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,889,039 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:28 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 3,725 | $3.80 | $14,155.00 |
DisclosureSEC source: 0001846253-23-000013 · edgardoc.xml · nonDerivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,893,216 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document |
| February 15, 2023 Filed Feb 18, 2023 00:28 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 9,184 | $3.80 | $34,899.20 |
DisclosureSEC source: 0001846253-23-000013 · edgardoc.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896,941 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units. Read SEC document |
| January 03, 2023 Filed Jan 4, 2023 23:03 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-23-001297 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2033-01-03 Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:05 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantCommon Stock | 79,665 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001017 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,906,125 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments beginning on December 7, 2023, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| December 28, 2022 Filed Dec 30, 2022 22:00 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 11,624 | $3.66 | $42,543.84 |
DisclosureSEC source: 0000899243-22-039581 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,826,460 Read SEC document |
| December 12, 2022 Filed Dec 14, 2022 22:00 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 150,000 | $3.77 | $564,765.00 |
DisclosureSEC source: 0000899243-22-038479 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,838,084 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.48 to $3.87. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 23:00 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 298,311 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0000899243-22-038123 · doc4.xml · derivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,311 Underlying: Common Stock · 298,311 shares Expires 2032-12-07 F1 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on June 7, 2023, and in 42 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:36 UTC | OmniAb, Inc. OABI · Entity 5294 | Tax withholdingCommon Stock | 17,266 | $3.35 | $57,841.10 |
DisclosureSEC source: 0000899243-22-037740 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,688,084 Read SEC document |
| November 30, 2022 Filed Dec 1, 2022 23:00 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 300,000 | $3.39 | $1,016,340.00 |
DisclosureSEC source: 0000899243-22-037303 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,705,350 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.9275 to $3.57. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2022 Filed Nov 10, 2022 01:30 UTC | OmniAb, Inc. OABI · Entity 5294 | PurchaseCommon Stock | 100,000 | $2.76 | $276,160.00 |
DisclosureSEC source: 0000899243-22-035469 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,405,350 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.6275 to $2.85. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerEmployee Stock Option (right to buy) · Derivative | 34,214 | Not disclosed Strike: $90.68 | Not disclosed |
DisclosureSEC source: 0000899243-22-035037 · doc4.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Former Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,214 shares Expires 2032-05-05 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F2 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:06 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Disposition to issuerCommon Stock | 20,304 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-035037 · doc4.xml · nonDerivative · entry 1 FOEHR MATTHEW W · CIK 0001237556 · Former Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,187 F1 · kind: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. F1 · price: Certain of the Reporting Person's equity awards were cancelled in connection with the separation of OmniAb, Inc. from the Issuer on November 1, 2022. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 298,311 | Not disclosed Strike: $10.41 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 10 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,311 Underlying: Common Stock · 298,311 shares Expires 2032-05-05 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F8 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 5, 2022, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 56,233 | Not disclosed Strike: $20.36 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 9 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,233 Underlying: Common Stock · 56,233 shares Expires 2031-02-03 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F7 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 3, 2021, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 142,168 | Not disclosed Strike: $10.98 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 8 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,168 Underlying: Common Stock · 142,168 shares Expires 2030-02-13 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F6 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 13, 2020, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 146,325 | Not disclosed Strike: $13.54 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 7 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,325 Underlying: Common Stock · 146,325 shares Expires 2029-02-11 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F5 · derivative.exercise_date: The stock option vests and is exercisable as to 12.5% of the underlying shares on August 11, 2019, and in 42 substantially equal monthly installments thereafter. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 86,790 | Not disclosed Strike: $18.24 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 6 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,790 Underlying: Common Stock · 86,790 shares Expires 2028-03-02 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 104,231 | Not disclosed Strike: $11.52 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 5 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,231 Underlying: Common Stock · 104,231 shares Expires 2027-02-24 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 111,038 | Not disclosed Strike: $9.84 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 4 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,038 Underlying: Common Stock · 111,038 shares Expires 2026-02-11 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 172,768 | Not disclosed Strike: $6.46 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 3 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 172,768 Underlying: Common Stock · 172,768 shares Expires 2025-02-10 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:10 UTC | OmniAb, Inc. OABI · Entity 5294 | GrantStock Option · Derivative | 270,595 | Not disclosed Strike: $8.54 | Not disclosed |
DisclosureSEC source: 0000899243-22-035050 · doc4.xml · derivative · entry 2 FOEHR MATTHEW W · CIK 0001237556 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,595 Underlying: Common Stock · 270,595 shares Expires 2024-02-12 F1 · kind: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F1 · price: Pursuant to the business combination of Avista Public Acquisition Corp. II and OmniAb, Inc. ("Legacy OmniAb"), as contemplated by an agreement and plan of merger, dated March 23, 2022 (the "Merger Agreement"), each share of common stock, option and award of restricted stock unit of Legacy OmniAb automatically converted into the right to receive securities of the Issuer with the same terms and conditions in accordance with an exchange ratio described in the Merger Agreement. F4 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.